Evaluating the risk-benefit ratio of adjuvant trastuzumab-based therapy for t1a,bN0M0 her2-positive breast carcinomas

M. J. Rodrigues, L. Albiges-sauvin, J. Wassermann, P. H. Cottu

    Research output: Contribution to journalLetterpeer-review

    5 Citations (Scopus)
    Original languageEnglish
    Pages (from-to)2530
    Number of pages1
    JournalAnnals of Oncology
    Volume22
    Issue number11
    DOIs
    Publication statusPublished - 1 Jan 2011

    Cite this